Unraveling Parkinson's Disease: A Comprehensive Overview for Healthcare Professionals
OthersPage Navigation
Introduction
Parkinson's disease (PD) is a chronic, progressive neurodegenerative disorder that primarily affects movement. Characterized by the degeneration of dopaminergic neurons in the substantia nigra, PD presents a complex clinical challenge necessitating a comprehensive understanding by healthcare professionals.
Etiology and Pathophysiology
While the exact cause of PD remains unknown, it is thought to result from a combination of genetic and environmental factors. Pathophysiologically, the loss of dopaminergic neurons leads to an imbalance in the basal ganglia's neurotransmitter levels, resulting in the motor symptoms of PD.
Clinical Manifestations
PD typically manifests with bradykinesia, rigidity, and resting tremor. Non-motor symptoms such as autonomic dysfunction, cognitive impairment, and mood disorders may also be present. The disease is progressive, with symptoms worsening over time.
Diagnosis
Diagnosis of PD is primarily clinical, based on the presence of cardinal motor symptoms and response to dopaminergic therapy. Neuroimaging can support the diagnosis, but it is not routinely used due to its limited sensitivity and specificity.
Treatment
Management of PD involves pharmacological therapy to enhance dopaminergic function, alongside non-pharmacological interventions such as physical therapy. Deep brain stimulation may be considered in advanced cases.
Conclusion
In conclusion, Parkinson's disease is a complex neurodegenerative disorder that requires a comprehensive and multidisciplinary approach to management. As healthcare professionals, it is essential to stay updated on the latest advancements in PD research to provide optimal care to our patients.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge